Reach Us +44-1764-910199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


Development of a Customized TaqMan® Array Card for Simultaneous Detection of 32 Respiratory Pathogens

Background: Syndromic testing with a rapid and complete diagnostic panel would be extremely useful for routine respiratory testing.

Objective: We developed and validated a real-time PCR-based Taqman array card (TAC) including several pathogens specific for immuno-compromised patients, using sequences designed and supported by the manufacturer.

Study design: Analytical validation was performed in 2 phases. Phase 1 testing was performed in 96-well plates and included efficiency, reactivity and sensitivity testing. The assays selected after phase 1 were validated in TAC format in phase 2 which included analytical sensitivity (LoD), reactivity, specificity and reproducibility testing. Clinical validation was performed in phase 3 by testing respiratory samples that were sent to the lab between December 2016 and May 2017. Results: In total, 90 assays were tested in phase 1 of which 43 were retained for further validation in TAC format. Seven of the 43 assays did not meet the predefined criterion of efficiency ≥ 80%, but were accepted for further testing in phase 2 and 3 due to lack of alternatives. All 43 targets together detected 89% (481/539) of positives included in the reactivity testing in phase 1 and 98% (246/252) of positives in phase 2. All tested assays showed excellent analytical sensitivity, with LoD ranging from 1 to 100 copies/μL. An overall specificity of 99.96% was found. Reproducibility ranged from 76%-100%, with a mean of 91%. For the clinical validation, a total number of 428 samples were tested, with an overall positivity rate of 56.3% and a co-infection rate of 15.9%. 15 results (4% of total number of positives) were not confirmed and considered false positives. One result (0.2%) was considered false negative.

Conclusion: This syndromic panel was analytically and clinically validated and will be implemented for routine respiratory testing in the Erasme University Hospital in high risk patient populations.

Author(s): Deborah Steensels, Marie-Luce Delforge, Katrien Lagrou, Kurt Beuselinck and Isabel Montesinos

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

Flyer image

Abstracted/Indexed in

  • Publons
  • Secret Search Engine Labs